Culture Medium Brand Ranking

Thermo Fisher Scientific (China) Co., Ltd.

Life Technologies' earliest history can be traced back to 1962, when GIBCO (Grand Island Biological Company) was established in New York, USA. By 1983, GIBCO merged with Bethesda Research Laboratories, enabling Life Technologies as the new company name. The Gibco brand has always been committed to cell culture research and application fields, providing high-quality products and services to the biopharmaceutical industry. With its rich experience, professional knowledge, firm commitment and continuous innovation, Gibco has successfully supported the development and production of more than 230 commercial biopharmaceuticals. It has been widely verified by the industry and will continue to meet the development of the biopharmaceutical industry. Demand to support the technological development and leapfrogging in the field of human big health. From the first time you culture cells and throughout your career, Gibco can assist you with trusted culture formulas that match your experiments and a range of proven, amplified solutions. You bring your products to the market. Gibco culture medium, serum, additives, cells, cell culture reagents and Gibco 's professional team aims to provide better support for your research. Gibco 's technical experts, scientists and regulatory team are ready to serve you and help you advance your work.

walson groupe

Huaian walson groupe Co.,ltd founded in 2023 which have two factory : Huaian walson greenhouse technology and Taizhou huayue plastic products co.,ltd. Which are keep running export business over 20years. Our main products are Garbage bag,aluminum foil container,plastic disposable container,biodegradable disposable tableware,kitchen supplies,garden bed ,greenhouse and so on.

Sigma-Aldrich (Shanghai) Trading Co., Ltd.

As a global technology company, Merck’s mission is to solve difficult problems in the life sciences. The company's tools, services and digital platforms empower scientists and engineers at all stages to enable scientific breakthroughs. In addition to providing cutting-edge technology and high-quality products, it also provides novel services and novel therapies in the diagnosis, research, development and manufacturing of biologics. Committed to simplify, accelerate and optimize research and biotechnology production. From labs to e-commerce platforms, the company focuses on every customer experience, driving and accelerating research, manufacturing and development by helping scientists around the world acquire product, literature and technical expertise. Cell culture is the basis of life science research. Whether you want to establish relevant cellular models to explore complex biology, establish drug discovery and drug development programs, or produce recombinant proteins or related therapies, it can provide you with the products and services necessary to drive scientific progress. The company's cell culture workflow product line, advanced cell culture solutions, cell counting and imaging equipment, culture tools, extracellular matrix, hydrogels, sterile filter consumables, reagents, culture media, serum and growth factors to ensure The quality of 2D and 3D cell culture experiments laid the foundation.

OptiMA Biotech Co., Ltd.

Shanghai Aopumai Biotechnology Co., Ltd. (stock abbreviation: Aopumai, stock code: 688293) was established in 2013. It is a high-tech biotechnology enterprise focusing on providing cell culture solutions and end-to-end CDMO services. Oupmai has 4 production bases that meet GMP standards, with a total area of ​​more than 18,000 square meters, and the quality management system has obtained ISO9001:2015 certification (TÜV NORD, Germany). Another new headquarters with a total area of ​​about 30,000 square meters is in the construction stage. In 2022, Oupmai landed on the Science and Technology Innovation Board and embarked on a new journey. Oupmai will continue to rely on the international advanced technology research and development team and a complete commercial production quality management system, adhere to the quality policy of "highest craftsmanship and best quality", and continue to optimize and innovate. With the core principle of providing diversified, high-performance, highly stable quality products, and with a fast response and continuous service attitude, Oupmai provides excellent, stable and personalized "one-stop" cell culture solutions, becoming a global pharmaceutical manufacturing solution. An important strategic partner of the company. Oupmai’s medium business provides the world’s leading chemical composition-definition/serum-free cell culture medium products, including shelf-type commercial culture medium, customized culture medium and designated formula commissioned production services. With its excellent product performance, a total of 200+ pharmaceutical R&D pipelines with determined pilot processes use the company's cell culture medium products. Oupmai CDMO services provide end-to-end overall solutions for the research and development and production of biopharmaceuticals. The CDMO production base complies with the GMP standard and serves every stage of biopharmaceuticals from antibody discovery to commercial production up to 2000L. With its professional service, the company has successfully delivered more than 200 biopharmaceutical development and production projects, and has successfully helped global partners to pass the China-US IND application.

tech Co., Ltd.

Baiyin Bio is an international biopharmaceutical CDMO company with the ability to independently develop and produce various serum-free cell culture media. Baiyin Bio is committed to providing global biopharmaceutical companies with one-stop CDMO outsourcing services such as cell line development, process development, process amplification, clinical material production, clinical application, and cGMP production of listed products for biopharmaceutical companies; Culture medium product development and production; quality control consulting services. Baiyin Bio is headquartered in Beijing and has established Suzhou Taicang Production and R&D Base and Suzhou Biopharma Industrial Park (BioBAY) R&D Center in mainland China. Taicang's production and R&D base area exceeds 12,000 square meters, with the capacity of culture medium production, protein production, plasmid production, virus production and preparation production. With its rich production lines and sufficient production capacity, Baiyinnuo Bio can efficiently provide global customers with high efficiency. Low cost, customized, diverse products and services. At the same time, the R&D centers in Taicang and Suzhou allow Baiyin Bio to have strong R&D capabilities and can provide personalized R&D services to the needs of different customers. The founding team members of Baiyin Bio are experienced and have strong skills. Their inspiration has brought a large number of internationally renowned experts and talents focusing on CDMO and supply chain services around Baiyin Bio . Their participation has further increased Baiyin Bio. The technology reserves of Biological have enriched the product types of Biological and improved the product quality of Biological and made Biological’s CDMO operation capabilities, products produced, and service quality provided by Biological and Biological comparatively high international standards.

Tianxinhe (Suzhou) Biotechnology Co., Ltd.

Zhongsheng Tianxinhe (Wuxi) Biotechnology Co., Ltd., a service provider and supplier of biopharmaceutical process technology and solutions, focuses on improving the independent and controllable capabilities of China's upstream raw materials and equipment, and accelerating the development of the biopharmaceutical industry. Tianxinhe focuses on the research and production of personalized cell culture media, bioreactor process design and manufacturing, large-scale animal cell culture process technology research, and development and transfer of biological process technology. Based on this, it has constructed the biopharmaceutical process technology technology. Development platform. Tianxinhe (Suzhou) Biotechnology Co., Ltd. is a wholly-owned subsidiary of Zhongsheng Tianxinhe (Wuxi) Biotechnology Co., Ltd. It covers a total area of ​​8,000 square meters in Wujiang, Suzhou, and has built a 5,000 square meters of cell culture medium that meets GMP requirements. Workshop, bioreactor production workshop and R&D laboratory. The company has passed the ISO9001:2015 quality management system and ISO14001:2015 environmental management system certification. The annual output of cell culture medium reaches 150 tons, and the annual output of bioreactors is more than 50 sets, which can meet the dynamic needs of the development of the biopharmaceutical industry such as antibodies and vaccines. .

Gracell Biotechnologies (Shanghai) Co., Ltd.

The origin of HyClone™ Laboratories is indeed a plot twist! It began in 1967 when Dr. Rex Spendlove, who was then a professor at Utah State University, was studying a viral disease that is deadly to children. His research is inseparable from fetal bovine serum (FBS). The quality of fetal cattle serum was so poor that Dr. Spendlove had to develop some methods to produce high-quality serum by himself. Finally, HyClone™ was obtained, thus creating a variety of serum collection, filtration and processing technologies used by manufacturers of cell culture products. Cytiva is a global technology and service provider committed to promoting unseen technologies and accelerating extraordinary therapies. The company's long history goes back hundreds of years ago. In 2020, it became an independently operated company under the Danaher Group, and has embarked on a new journey. From basic biological research to the research and development of innovative vaccines, from biomedicine to the development of new cell and gene therapies, the work of the company’s customers is closely related to life. The company's products and services provide strong support to customers, helping them accelerate research, reduce costs and increase efficiency, thereby benefiting patients around the world.

Auscom Biotech (Nantong) Co., Ltd.

Aoskang Bio (Nantong) Co., Ltd. was established in 2017 and is headquartered in Haimen Biotechnology Park, Nantong City, Jiangsu Province. As a CDMO company focusing on the macromolecule field, ASK Biosciences can provide one-stop CMC solutions from candidate molecules to clinical and commercial production. As a "Party B company with Party A's new drug development concept", the core technical team of Aoscon has rich experience in biologics CMC and registration. Members of the CMC technical team have led the development of INDnabling CMC, Sino-US IND application, NDA On-site inspection (PAI) for production reporting and pre-marketing. Aoscon Bio has raised a total of 3 billion yuan in financing and invested 2 billion yuan in platform hardware construction, continuing to provide the industry with high-quality CDMO services for biomacromolecule drugs. The company obtained a drug production license in January 2019, and passed the National Bureau of Administration and the pre-market on-site verification (PAI) for registration of the National Bureau and Provincial Bureau and GMP compliance two-in-one products in March 2021, July 2022 and October 2023. The company undertakes and delivers the CMC development and application work for hundreds of monoclonal antibodies, double antibodies, multi-antibody, ADCs, nano-antibody, fusion protein, FVIII, FVIII-Fc-PEG and other projects. As a Party B company with the "Party A's new drug development concept", the core technical team of Aoscon Bio has rich experience in biologics CMC and registration. Our CMC technical team members have led the INDnabling CMC development work, Sino-US IND application, NDA production reporting and pre-market on-site verification (PAI) for multiple projects. We provide one-stop research and development and production services for drugs such as monoclonal antibodies, dual antibodies, fusion proteins, and ADCs.

Shanghai Bioagilytix Biotechnology Co., Ltd.

Shanghai Beianji Biotechnology Co., Ltd. was established in December 2014 by Professor Tan Wensong's team of East China University of Science and Technology. It focuses on large-scale high-density serum-free suspension culture technology services and raw material development and manufacturing, providing biopharmaceutical companies with cells from the majority of cells. High-quality one-stop service from culture process development and optimization, medium formulation design to medium processing and manufacturing. The company's headquarters and R&D center are located in Zhangjiang Pharmaceutical Valley, Shanghai, and the Phase II production base (Shanghai Beijin Biotechnology Co., Ltd.) is located in Jinshan, Shanghai. Since its establishment in 2014, Beanji has grown very rapidly and has independently developed nearly 100 catalog-type serum-free culture media for different cells, including Eden series CHO cell serum-free culture media for antibody protein expression, for cell therapy. The HIPP series of immune effector cells have serum-free culture medium, which is used for vaccine production such as Vero, HEK293, MDCK, PK15, BHK, MDBK, insect cells, etc. The product can support high-density culture and efficient amplification of cells, and its effect is better than other well-known culture medium products. It is easier to purify and downstream processing, effectively improving the safety and yield of cell products, and greatly reducing production costs for customers. The product quality and technical service level have surpassed imported similar products and are highly praised by domestic biopharmaceutical companies. To date, Beanji supports more than 80 clinical application projects in the biopharmaceutical industry such as antibodies, vaccines, and cell/gene therapy, providing nearly 100 cell culture technology services, and has many domestic and international breakthrough project results. In the field of antibodies, Beanji helps customers to launch the first domestic antibody fusion protein drug that uses domestic medium formulas and processes. In the field of vaccines, the human/abvian influenza vaccine production based on MDCK cell serum-free suspension culture technology and the human vaccine (Phase III clinical) project based on VERO cell serum-free culture technology have been completed. In the field of cell therapy, the HIPP-T009 series of immune effector cell culture media independently developed by Beanji has become a real serum-free medium for high-density culture and maintenance of CAR-T cells and NK cells released in China, and is also used in China. Domestic culture medium that has been applied for clinical trials of cell therapy and has passed the CDE review. By the end of 2021, the Beanji Phase II culture medium production base (Shanghai Beijin Biotechnology Co., Ltd.) will be fully put into production. The base is a world-class factory built in accordance with the requirements of ISO13485:2016 quality management system, GMP and MDSAP multi-system, and adopts LSS Lean 6 Sigma system for production management. It has achieved a thousand upgrades, tens of thousands of upgrades, and tens of thousands of upgrades to low-temperature needle mill powder technology. Consistent amplification, the maximum batch volume can reach 100,000 liters, with an annual production capacity of 55 million liters of powder culture medium and 250,000 liters of liquid culture medium. Beanji's products meet the requirements for culture medium by relevant regulations such as US FDA certification and EU product registration declaration. Beanji is committed to supporting the research and development and production of innovative biological drugs such as antibodies, vaccines, cell therapy, etc. with stable and reliable high-quality culture medium products and services, and benefiting human health.

Lonza (Shanghai) International Trade Co., Ltd.

Lonsha provides a wide range of services and products to the pharmaceutical, consumer health and nutrition industries, from early discovery to customized development and production of active pharmaceutical ingredients to innovative dosage forms. Longsha ’s scale and resources show that Longsha has the strength to provide customers with one-stop solutions to help people recover, keep their body and mind happy and enjoy a better life. In 2021, Longsha will support more than 780 preclinical and clinical small molecule/macromolecular drugs, as well as 245 commercial stages of small molecule/macromolecular drugs, and produce up to 250 billion capsules. In 1897, Ronsha was born in the Alps in Switzerland. To date, its business has spread to five continents around the world. With approximately 16,000 full-time employees, the efficient team and each of them have made significant changes to Longsha ’s business and region and country. Longsha ’s business benefits from global supply chains, but Longsha has been working hard to maintain flexibility to meet local market demand. Being a responsible company and committed to sustainable development is Longsha's firm commitment and the basis for Longsha to do all its work well. Reducing environmental impact, saving energy and natural resources, and continuously improving people's quality of life are the core of corporate culture. Longsha’s “Zero Accident Vision” plan is a good proof that Longsha strives to achieve gig work-related accidents, zero environmental accidents, zero product transportation accidents and zero production process accidents. Longsha makes every effort to attract and retain outstanding talents and actively achieve significant changes for Longsha 's company and the region. In 2021, the company's sales reached CHF 5.4 billion, and its core business earnings before interest, tax, depreciation and amortization (EBITDA) reached CHF 1.7 billion. Longsha shares are listed on the Swiss Stock Exchange and the Swiss Market Index (SMI), respectively, and are also listed on the Singapore Exchange for secondary listing.

BIO (Shanghai) Trading Co., Ltd.

Founded in 1993, STEMCELL provides high-quality cell culture media, cell isolation technology, instruments and supporting products to scientists engaged in stem cell, immunology, cancer, regenerative medicine and cell therapy research around the world. STEMCELL is committed to promoting diversity and inclusion in stem cells, life sciences and other fields through advanced knowledge and science and technology; and improving lives through investments in sustainability, community and social responsibility. STEMCELL is rooted in scientific rigorous expertise and promotes the pursuit of scientific knowledge and promotes the development of life science by providing high-quality innovative reagents, tools and services to support life science research. STEMCELL's main products are cell culture media and supplements, cell isolation products, cell storage media, cytokines and proteins, substrates and cultures used to simulate the physiological environment around cells, small molecule compounds, cell culture dishes and other consumables, 20 types of products such as instruments and software, involving 19 different research fields.

Corning (Shanghai) Management Co., Ltd.

Corning is one of the world's advanced innovators in the field of materials science and has been committed to life-changing innovation. Corning combines its profound expertise in glass science, ceramic science and optical physics with deep production and engineering capabilities to create numerous products that disrupt industries and improve people's lives. Corning has been successful by continuously investing in R&D and engineering to combine materials with process innovation in a unique way and establishing close trust relationships with global industry customers. Corning has a diversified business scope and good collaboration capabilities to meet the ever-evolving market needs and help customers capture more opportunities in dynamic markets. Today, Corning's products cover optical communications, mobile consumer electronics, display technology, automotive applications and life sciences. Corning's industry's advanced products include damage-resistant cover glass for mobile devices; precision glass for advanced displays; fiber optic, wireless communication technology and connector solutions for modern communication networks; trusted to promote drug development and transportation products; and air purification technology for automobiles and trucks.

Cytiva (formerly part of GE Healthcare)

Delivers high-quality cell culture media, sera, and supplements for biopharmaceutical and research applications.

MP Biomedicals, LLC

Provides high-quality life science and molecular biology products, including reagents, kits, and instruments for research and diagnostics.

Merck KGaA

A division of Merck, offering a comprehensive portfolio of lab products, including filtration, purification, and lab water systems.

Becton, Dickinson and Company

Provides flow cytometry, cell imaging, and molecular biology products for research and clinical diagnostics.

Sigma-Aldrich Corporation

Sigma-Aldrich provides high-quality laboratory equipment, including thin film evaporators, for research and industrial applications.

Bole Life Medical Products (Shanghai) Co., Ltd.

Bio-Rad is in a high position in developing, manufacturing and selling a variety of innovative products for the life science research and clinical diagnosis markets. For more than 65 years, the company's products have promoted scientific discoveries and improved healthcare. Clients include universities and research institutions, hospitals, public health and commercial laboratories, and biotechnology, pharmaceutical and application research laboratories, including food safety and environmental quality. Life Science Research Products Bio-Rad is one of the world's well-known life science companies that provide instruments, software, consumables, reagents and related content for cell biology, gene expression, protein purification, protein quantification, drug discovery and production, food safety and science education. . Our products and solutions are based on technologies for isolating, purifying, identifying, analyzing, and amplifying biological materials such as antibodies, proteins, nucleic acids, cells and bacteria. Clinical diagnostic products As a well-known supplier of in vitro diagnostic supplies, the company's diagnostic products and systems utilize various technologies and provide valuable clinical information for the blood transfusion, diabetes monitoring, autoimmune and infectious disease testing markets. These products are used to support the diagnosis, monitoring and treatment of diseases and other medical conditions. Digital Biology The unique micro droplet digitalization technology has unparalleled accuracy and absolute quantitative analysis of target DNA or RNA molecules, dispersing the samples into tens of thousands of independent micro droplet systems, thus providing life science research, clinical diagnosis, environmental monitoring and food safety. Testing provides extremely sensitive and accurate digital answers.

Changzhou Qifu Antai Composite Materials Technology Co., Ltd.

Changzhou Qifu Antai Composite Materials Technology Co., Ltd. (abbreviated as: Antai Composite Materials, English abbreviation: ATCC), was established in 2017. Its shareholders include Antai Technology, National Advanced Manufacturing Fund, Zhongguancun Mother Fund, China Steel Research Dahui Jiuding, Changzhou Municipal Government Investment Fund, Changhaoxin Group, etc., have registered capital exceeding RMB 1.4 billion. In May 2018, the company acquired Germany's COTESA GmbH (Airbus Boeing composite material supplier) and Germany's EC (European and American super luxury car composite material parts supplier). It now has three bases and two centers (Mittweida base in Germany, Mochau base in Germany, Changzhou factory (Phase I and II), European R&D center and Sino-German Joint Engineering and Technology Center). The company's core business is aviation-grade carbon fiber composite structural parts, covering aerospace, rail transit, new energy vehicles and other fields. As a start-up multinational business enterprise, Antai Composite has always adhered to the integrated innovation strategic route of introduction, digestion, absorption and improvement, adhered to the original intention of "international standards + China Intelligent Manufacturing", integrated the overall resources of the international supply chain, and provided services with advanced German technology. The country's major projects and projects are constantly deepening domestic incremental market opportunities, and are committed to becoming a multinational innovative enterprise in carbon fiber composite technology that breaks through the key core technologies of carbon fiber composite components and has high market recognition.

Sartorius Scientific Instruments (Beijing) Co., Ltd.

In 1870, Florenz Sartorius founded the company Sartorius, headquartered in Göttingen, Germany. Today, the company Sartorius has taken a leading position in the fields of mechanical electronics, biotechnology and environmental technology. For more than 150 years, Sedolis has been constantly innovating and improving weighing technology and has always been at the forefront of the development of weighing technology. Sedolis' products are spread all over the world and have gained a high reputation. From Madame Curie's laboratory to NASA, from the benchmark balance of the National Institute of Metrics to the balance of the International Olympic Chemistry Competition of Peking University... all embodies Sedolis' contribution to high-tech development. Today, many diseases are still incurable. Hundreds of millions of people do not have access to economical and safe medicines. Sedolis’ biopharmaceutical customers are working to develop new drugs to improve people’s lives. To do this, they need strong partners to help them succeed. The Sedolis Group is an internationally leading partner in the biopharmaceutical industry and research field. From creativity to production, it has been helping biotechnologists and engineers around the world develop and develop drugs, so that more people can get better drugs. For the biopharmaceuticals, chemicals, food and beverage industries and academic fields, Sedolis is confident that it can meet the growing quality, efficiency, accuracy, compliance and production through instrumentation, intuitive software, internship training and complete services. demand. Rapidly start and simplify workflows with product and platform solution experiences to fully meet your laboratory and bioprocess application needs. From consumables and laboratory water purification systems to industry-leading weighing technology, Sedolis' advanced solutions also include fluid management, fermentation, and laboratory filtration.